Carpenter CCJ, Cooper DA, Fischl MA.
et al. Antiretroviral therapy in adults: updated recommendations of the International
AIDS Society-USA Panel. JAMA.2000;283:381-390.
US Department of Health and Human Services and the Henry J. Kaiser
Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults
and adolescents. Available at: http://www.hivatis.org/trtgdlns.html. Accessibility
verified June 8, 2001.
Kempf DJ, Rode RA, Xu Y.
et al. The duration of viral suppression during protease inhibitor therapy
for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS.1998;12:F9-F14.
Raboud JM, Montaner JS, Conway B.
et al. Suppression of plasma viral load below 20 copies/mL is required to
achieve a long-term response to therapy. AIDS.1998;12:1619-1624.
Havlir DV, Marschner IC, Hirsch MS.
et al. for the AIDS Clinical Trials Group Study 343 Team. Maintenance antiretroviral therapies in HIV-infected subjects with
undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med.1998;339:1261-1268.
Reijers MH, Weverling GJ, Jurriaans S.
et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected
Pialoux G, Raffi F, Brun-Vezinet F.
et al. for the Trilège (Agence Nationale de Recherches sur le SIDA
072) Study Team. A randomized trial of three maintenance regimens given after three
months of induction therapy with zidovudine, lamivudine, and indinavir in
previously untreated HIV-1–infected patients. N Engl J Med.1998;339:1269-1276.
Günthard HF, Frost SD, Leigh-Brown AJ.
et al. Evolution of envelope sequences of human immunodeficiency virus type
1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol.1999;73:9404-9412.
Ramratnam B, Mittler JE, Zhang L.
et al. The decay of the latent reservoir of replication-competent HIV-1 is
inversely correlated with the extent of residual viral replication during
prolonged anti-retroviral therapy. Nat Med.2000;6:82-85.
Martinez-Picado J, DePasquale MP, Kartsonis N.
et al. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci U S A.2000;97:10948-10953.
Gulick RM, Mellors JW, Havlir D.
et al. Treatment with indinavir, zidovudine, and lamivudine in adults with
human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med.1997;337:734-739.
Drusano GL, Bilello JA, Stein DS.
et al. Factors influencing the emergence of resistance to indinavir. J Infect Dis.1998;178:360-367.
Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika.1994;81:515-526.
Paris D, Ledergerber B, Weber R.
et al. Incidence and predictors of virologic failure of antiretroviral triple-drug
therapy in a community-based cohort. AIDS Res Hum Retroviruses.1999;15:1631-1638.
Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment
failure in patients with HIV starting a protease inhibitor. AIDS.1998;12:2161-2167.
Raboud JM, Rae S, Hogg RS.
et al. Suppression of plasma virus load below the detection limit of a human
immunodeficiency virus kit is associated with longer virologic response than
suppression below the limit of quantitation. J Infect Dis.1999;180:1347-1350.
Powderly WG, Saag MS, Chapman S.
et al. Predictors of optimal virological response to potent antiretroviral
Pilcher CD, Miller WC, Beatty ZA, Eron JJ. Detectable HIV-1 RNA at levels below quantifiable limits by amplicor
HIV-1 monitor is associated with virologic relapse on antiretroviral therapy. AIDS.1999;13:1337-1342.
Paredes R, Mocroft A, Kirk O.
et al. Predictors of virological success and ensuing failure in HIV-positive
patients starting highly active antiretroviral therapy in Europe. Arch Intern Med.2000;160:1123-1132.
Wit F, van Leeuwen R, Weverling GJ.
et al. Outcome and predictors of failure of highly active antiretroviral therapy. J Infect Dis.1999;179:790-798.
Grabar S, Pradier C, Le Corfec E.
et al. Factors associated with clinical and virological failure in patients
receiving a triple therapy including a protease inhibitor. AIDS.2000;14:141-149.
Paterson DL, Swindells S, Mohr J.
et al. Adherence to protease inhibitor therapy and outcomes in patients with
HIV infection. Ann Intern Med.2000;133:21-30.
Acosta EP, Havlir DV, Richman DD.
et al. Pharmacodynamics (PD) of indinavir (IDV) in protease-naive HIV-infected
patients receiving ZDV and 3TC. From: Seventh Conference on Retroviruses and Opportunistic
Infections, San Francisco, California, January 30-February 2, 2000.
Alexandria, Va: Foundation for Retrovirology and Human Health; 2000:162. Abstract
O'Brien T, McDermott D, Ioannidis J.
et al. Effect of chemokine receptor gene polymorphisms on the response to
potent antiretroviral therapy. AIDS.2000;14:821-826.
O'Brien WA, Grovit-Ferbas K, Namazi A.
et al. Human immunodeficiency virus-type 1 replication can be increased in
peripheral blood of seropositive patients after influenza vaccination. Blood.1995;86:1082-1089.
Coffin JM. HIV population dynamics in vivo. Science.1995;267:483-489.
Coffin JM. Genetic diversity and evolution of retroviruses. Curr Top Microbiol Immunol.1992;176:143-164.
Temin HM. Retrovirus variation and reverse transcription. Proc Natl Acad Sci U S A.1993;90:6900-6903.
Clavel F, Hoggan MD, Willey RL.
et al. Genetic recombination of human immunodeficiency virus. J Virol.1989;63:1455-1459.
Grossman Z, Feinberg MB, Paul WE. Multiple modes of cellular activation and virus transmission in HIV
infection. Proc Natl Acad Sci U S A.1998;95:6314-6319.
Grossman Z, Polis M, Feinberg MB.
et al. Ongoing HIV dissemination during HAART. Nat Med.1999;5:1099-1104.
Haslett PA, Nixon DF, Shen Z.
et al. Strong human immunodeficiency virus (HIV)-specific CD4+ T-cell responses
in a cohort of chronically infected patients are associated with interruptions
in anti-HIV chemotherapy. J Infect Dis.2000;181:1264-1272.
Zhang L, Ramratnam B, Tenner-Racz K.
et al. Quantifying residual HIV-1 replication in patients receiving combination
antiretroviral therapy. N Engl J Med.1999;340:1605-1613.
Furtado MR, Callaway DS, Phair JP.
et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear
cells in patients receiving potent antiretroviral therapy. N Engl J Med.1999;340:1614-1622.
Yerly S, Kaiser L, Perneger TV.
et al. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. AIDS.2000;14:243-249.
Dornadula G, Zhang H, VanUitert B.
et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly
active antiretroviral therapy. JAMA.1999;282:1627-1632.
Zennou V, Mammano F, Paulous S.
et al. Loss of viral fitness associated with multiple Gag and Gag-Pol processing
defects in human immunodeficiency virus type 1 variants selected for resistance
to protease inhibitors in vivo. J Virol.1998;72:3300-3306.